Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials
Alex Z. Wang(National Institutes of Health), Peter A. Pinto(National Institutes of Health), John F. Ward(The University of Texas MD Anderson Cancer Center), Pilar Laguna(Istanbul Medipol University), Nitin Yerram(National Institutes of Health), Samir S. Taneja(NYU Langone Health), Rafael Sanchez‐Salas(Institute Mutualiste Montsouris), Sherif Mehralivand(National Institutes of Health), Jean de la Rosette(Radboud University Nijmegen), Michael Ahdoot(National Institutes of Health), Luke O’Connor(National Institutes of Health), Amir H. Lebastchi(University of Southern California), Arvin K. George(Johns Hopkins University)
Cited by 11
Related Papers
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
|New England Journal of Medicine|2003|2k
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: Indications, Complications, and Outcomes in 5803 Patients
|Journal of Endourology|2011|818
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
|The Lancet Infectious Diseases|2015|262